Being a physicist with a background in high energy physics, nuclear physics and MRI, I was working with my research team in Paris in a scientific and yet clinical environment strongly oriented towards translational research (University Paris Diderot, Sorbonne Paris Cité, Hôpital Beaujon, Paris, France).
I spent half of my scientific career in industry and half in academia. During my PhD in high energy physics (DESY, Deutsches Elektronen Synchrotron, Hamburg, Germany) I worked on quantum electrodynamics and chromodynamics and developed a neural-network based system to identify electrons in inelastic elementary particle collisions. After my PhD (1997) I took a position at Philips Medical Systems Research Laboratories in Hamburg, Germany. My main focus of research was in the domain of MRI and in particular in the field of MR-elastography (MRE).
In 2004 I decided to leave the industrial research in order to further develop my academic career. I followed a call to the “Laboratoire Ondes et Acoustique”, ESPCI, Paris, France and was offered a 3 years position as research director (CNRS) in order to establish a MRI group. My academic research activities were accompanied by collaboration with a newly founded ultrasound company (Supersonic Imaging, France). In 2007 I obtained a permanent position as research director at CNRS. This inspired me to move towards a new scientific environment offering me the possibilities to have access to three spatial scales: molecular and cellular level, small animal scale, and access to patients. Hence, I was able to develop more freely and comprehensively my own research program. My team in Paris had 9 members (2 permanent researchers, 5 post-docs and 2 PhD’s). I have close collaborations with many international research institutes: Neura Research Center Sydney, Australia; Prince of Wales Hospital, Hong Kong; University Hospital Lübeck, Germany; University of British Columbia, Vancouver, Canada; NIH, Bethesda, Maryland, USA; University of Minnesota, Minneapolis, USA; University of Oslo, Norway; The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, UK; Yonsei University College of Medicine, Seoul, and Samsung Hospital, Seoul, Korea.